Y Combinator-backed Aoa Raises $2.5M In Seed Funding To Develop First Non-invasive Test Set To Revolutionize The Future Of Ovarian Cancer Diagnostics
When detected early, almost 95% of ovarian cancer patients live more than five years after their diagnosis . AOA is a company on a mission to improve the early detection of cancer through the development of an innovative blood-based platform.
In this article
No tags related to this article.